Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05786781
Other study ID # UHCT22759
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 2, 2023
Est. completion date March 1, 2024

Study information

Verified date February 2023
Source Wuhan Union Hospital, China
Contact Bin Liang
Phone +8618086006235
Email 553954881@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, exploratory study to evaluate the value of transarterial CT angiography applying Nexaris Angio-CT in the interventional treatment of hemoptysis


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with massive hemoptysis(defined as more than 100mL per session or more than 300mL/day)or patients with recurrent mild to moderate hemoptysis and failed conservative treatment history Exclusion Criteria: - Pregnancy - Patients with a previous history of bronchial artery embolization - Uncorrectable severe infection, coagulation dysfunction, organ failure or cachexia, severe contrast agent allergy, and other interventional treatment contraindications

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transarterial CT angiography
Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis

Locations

Country Name City State
China Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Wuhan Union Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The accuracy rate of transarterial CT angiography in the identification of culprit vessel The accuracy rate of transarterial CT angiography in the identification of culprit vessel Intraoperative phase
Primary Total effective dose The total effective dose is the sum of the effective dose delivered by CT, fluoroscopy and DSA. The effective dose delivered by CT was determined using the dose length product (expressed as mGy*cm) and subsequently converted to the ED using a suitable conversion factor (0.014 mSv mGy-1 cm-1). The effective dose delivered by fluoroscopy and DSA was determined using the dose area product (expressed as mGy*cm2) and subsequently converted to the ED using a suitable conversion factor (0.12 mSv Gy-1cm-2). The dose length product and the dose area product were acquired on radiation dose structured reports. Intraoperative phase
Primary Early hemoptysis recurrence rate Recurrence rate of hemoptysis within 3 months after treatment 3 months after treatment
Secondary Technical success rate Technical success is defined as complete cessation of target blood flow confirmed by DSA Intraoperative phase
Secondary Immediate hemostasis success rate Hemostasis rate within 24 hours after treatment 24 hours after treatment
Secondary The amount of contrast agent consumed The amount of contrast agent consumed during treatment Intraoperative phase
See also
  Status Clinical Trial Phase
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Completed NCT00387374 - Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Phase 2
Completed NCT05513248 - Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019
Recruiting NCT05554731 - Development and Application of a New Balloon Catheter for Intraairway Hemostasis N/A
Recruiting NCT05634200 - Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan
Recruiting NCT06144398 - Single Use Flexible Bronchoscopes in Interventional Pulmonary Procedures N/A
Completed NCT01278199 - Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance N/A
Recruiting NCT04961528 - ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial. Phase 3
Completed NCT04087135 - Comparison of Intubation With Direct Laryngoscopy or Videolaryngoscopy in an Hemoptysis Simulated Situation on Human Cadaver Embalmed With Thiel's Method N/A
Recruiting NCT03270735 - A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection Phase 4
Completed NCT00929565 - Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy N/A
Completed NCT01171768 - The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis N/A
Withdrawn NCT01167764 - Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis Phase 3
Completed NCT03126968 - Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies Phase 2/Phase 3
Completed NCT02781597 - Efficacy of Tranexamic Acid in Hemoptysis Phase 3
Recruiting NCT05648656 - TXA Nebulization for the Treatment of Hemoptysis Phase 3
Completed NCT04771923 - Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding N/A
Recruiting NCT06145191 - Prophylactic Tranexamic Acid Versus Adrenaline During Flexible Bronchoscopy N/A
Completed NCT04770675 - Post Market Study to Collect Data for Software Recognizing the Anatomical Structures During Bronchoscopy.
Completed NCT06067997 - Prevalence Of Pulmonary Embolism In Patients With HEmoptysis (POPEIHE)